Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACROBAT: Upfront vs Pre-transplant Azacitidine or Chemotherapy in Higher-risk Myelodysplastic Syndromes
2019-003997-25Phase 3Active
- Sponsor
- GIMEMA
- Start
- Oct 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of azacitidine in myelodysplastic syndrome (MDS) (3 arms), sponsored by GIMEMA. Primary endpoint: Feasibility of HSCT (intent-to-treat). Started Oct 2020; status: active.
02
Drugs
azacitidine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2019-003997-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003997-25.